AVANIR Pharmaceuticals (FRA:AV2B) Days Inventory : 0.00 (As of Sep. 2014)

View and export this data going back to . Start your Free Trial

What is AVANIR Pharmaceuticals Days Inventory?

Days Inventory is also known as Days Sales of Inventory (DSI). AVANIR Pharmaceuticals's Average Total Inventories for the three months ended in Sep. 2014 was €0.56 Mil. AVANIR Pharmaceuticals's Cost of Goods Sold for the three months ended in Sep. 2014 was €-0.64 Mil.

The historical rank and industry rank for AVANIR Pharmaceuticals's Days Inventory or its related term are showing as below:

FRA:AV2B' s Days Inventory Range Over the Past 10 Years
Min: 0.73 Med: 125.63 Max: 27314.17
Current: 71.36

During the past 13 years, AVANIR Pharmaceuticals's highest Days Inventory was 27314.17. The lowest was 0.73. And the median was 125.63.

FRA:AV2B's Days Inventory is not ranked
in the Drug Manufacturers industry.
Industry Median: 158.365 vs FRA:AV2B: 71.36

AVANIR Pharmaceuticals's Days Inventory declined from Sep. 2013 (49.22) to Sep. 2014 (0.00).

Inventory Turnover measures how fast the company turns over its inventory within a year. AVANIR Pharmaceuticals's Inventory Turnover for the three months ended in Sep. 2014 was -1.14.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. AVANIR Pharmaceuticals's Inventory-to-Revenue for the three months ended in Sep. 2014 was 0.02.

AVANIR Pharmaceuticals Days Inventory Historical Data

The historical data trend for AVANIR Pharmaceuticals's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVANIR Pharmaceuticals Days Inventory Chart

AVANIR Pharmaceuticals Annual Data

Trend

Sep05

Sep06

Sep07

Sep08

Sep09

Sep10

Sep11

Sep12

Sep13

Sep14

Days Inventory

Get a 7-Day Free Trial

700.80

382.41

56.03

50.15

76.83

AVANIR Pharmaceuticals Quarterly Data
	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14
Days Inventory	Get a 7-Day Free Trial															49.22	47.03	41.67	35.53	-

Competitive Comparison of AVANIR Pharmaceuticals's Days Inventory

For the Drug Manufacturers - Specialty & Generic subindustry, AVANIR Pharmaceuticals's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AVANIR Pharmaceuticals's Days Inventory Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AVANIR Pharmaceuticals's Days Inventory distribution charts can be found below:

* The bar in red indicates where AVANIR Pharmaceuticals's Days Inventory falls into.

AVANIR Pharmaceuticals Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

AVANIR Pharmaceuticals's Days Inventory for the fiscal year that ended in Sep. 2014 is calculated as

	Days Inventory (A: Sep. 2014 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (A: Sep. 2013 )	+	Total Inventories (A: Sep. 2014 ))	/	count )	/	Cost of Goods Sold (A: Sep. 2014 )	*	Days in Period
=	( (0.531	+	0.62)	/	2 )	/	2.734	*	365
=	0.5755					/	2.734	*	365
=	76.83

AVANIR Pharmaceuticals's Days Inventory for the quarter that ended in Sep. 2014 is calculated as:

	Days Inventory (Q: Sep. 2014 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (Q: Jun. 2014 )	+	Total Inventories (Q: Sep. 2014 ))	/	count )	/	Cost of Goods Sold (Q: Sep. 2014 )	*	Days in Period
=	( (0.505	+	0.62)	/	2 )	/	-0.644	*	365 / 4
=	0.5625					/	-0.644	*	365 / 4
=	N/A

AVANIR Pharmaceuticals (FRA:AV2B) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

AVANIR Pharmaceuticals's Inventory Turnover for the three months ended in Sep. 2014 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	-0.644	/	0.5625
	=	-1.14

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

AVANIR Pharmaceuticals's Inventory to Revenue for the three months ended in Sep. 2014 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0.5625	/	25.379
	=	0.02

Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.

AVANIR Pharmaceuticals Days Inventory Related Terms

Thank you for viewing the detailed overview of AVANIR Pharmaceuticals's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

AVANIR Pharmaceuticals (FRA:AV2B) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AVANIR Pharmaceuticals (FRA:AV2B) » Definitions » Days Inventory

Traded in Other Exchanges

N/A

Address

Website

http://www.avanir.com

Avanir Pharmaceuticals was incorporated in California in August 1988 and was reincorporated in Delaware in March 2009. The Company is a biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders. The Company commenced promotion of NUEDEXTA in the United States in February 2011. The Company is also studying AVP-923 for use in different types of neuropathic pain. NUEDEXTA is the first and only FDA-approved treatment for pseudobulbar affect. NUEDEXTA is an combination of two components: dextromethorphan hydrobromide, the ingredient that is harmacologically active in the central nervous system, and quinidine sulfate, a metabolic inhibitor enabling dextromethorphan to reach therapeutic plasma concentrations. The Company currently markets NUEDEXTA to approximately 10,000 physicians and other healthcare providers who specialize in psychiatry, neurology or geriatric medicine and practice in outpatient or long-term care settings. NUEDEXTA may face competition from several products: Antidepressants, including Prozac, Celexa, Zoloft, Paxil, Elavil and Pamelor and others; Atypical antipsychotic agents, including Zyprexa, Risperdal, Seroquel, Abilify, Geodon and others; and Miscellaneous agents, including Symmetrel, Lithium and others. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substance Control Act, the Export Control Act and other present and future laws of general application.

AVANIR Pharmaceuticals (FRA:AV2B) Headlines

No Headlines